Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 20, 2020
Reporting Period: Events occurring between January 17, 2020, and January 24, 2020.
Status: Emerging Growth Company.
Key Financial Metrics
This filing reports a specific capital transaction rather than periodic financial performance. The filing text does not provide clear values for revenue, profit, cash flow, margins, or overall liquidity.
- Debt Reduction: $198,833 (inclusive of accrued and unpaid interest).
- Equity Issuance: 139,505,847 shares of common stock.
- Transaction Type: Debt-for-equity exchange.
Material Changes
The primary material change reported is the conversion of outstanding indebtedness into equity. Between January 17, 2020, and January 24, 2020, the Company issued 139,505,847 shares of common stock to settle $198,833 of debt. This transaction significantly altered the company's capital structure by reducing liabilities and increasing outstanding share count.
Guidance, Outlook, and Risks
Management Commentary: The Company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for the exemption from registration, citing that the transactions did not involve a public offering and were exchanges with existing security holders without solicitation commissions.
Risks and Contingencies: The filing notes that the Company reasonably believes all investors are accredited. No forward-looking guidance or specific risk factors beyond the standard disclosure of the transaction mechanics are provided in this document.
Investor Verification Checklist
- Verify the impact of the 139,505,847 new shares on existing shareholder dilution.
- Confirm the total outstanding debt remaining after the $198,833 reduction.
- Review the Company's most recent 10-K and 10-Q filings (referenced in the text) for updated cash position and liquidity status.
- Assess the valuation implied by the debt-to-equity conversion rate.